Eric Dutang Appointed as CFO at biolog-id
8.12.2021 18:08:00 EET | Business Wire | Press release
In alignment with its strategic plan for growth and readiness for going public, biolog-id, a global leader in the traceability of sensitive therapeutic products, reinforces its executive team by appointing Eric Dutang as Chief Financial Officer and Deputy CEO. Within biolog-id Executive Committee he will also oversee the Human Resources, Information Technology & Legal support functions. This appointment has come into effect on December 3rd, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005747/en/
Eric Dutang - CFO biolog-id (Photo: Business Wire)
Throughout his career, Eric Dutang has acquired an extensive experience and demonstrated his expertise in various financial sectors both for the European and North American markets. He began his career by carrying out audit assignments for French and American leading companies, before joining KPMG Transaction Services as Financial Due Diligence Advisor for 7 years. After that, he participated in the international development of listed French companies in Poland and China, before offering his competencies to Alvest, a company specialized in equipment for the aviation industry. In 2015, he joined the biopharmaceutical company Cellectis as Group CFO, where he undertook to transform various functions and conducted strategic fundraisings in the United States to support the group growth, including Initial Public Offering.
“I’m very excited to welcome Eric Dutang to the biolog-id team. His deep-business background, especially in publicly traded companies, is a great addition to our organization,” says Troy Hilsenroth, CEO at biolog-id. “His expertise straddling both the French and the US markets will make the necessary connection between our historical site and our expansion projects.”
“It is a real honor to join biolog-id in this thrilling adventure. Due to my previous experience in a similar healthcare structure and the experience I’ve earned with listed companies, I’m confident that I may positively contribute the biolog-id development. I’m committed to making the forthcoming challenges a success.”, explains Eric Dutang.
Eric (48) is French native and resides in New-York USA. He is certified as a Public Accountant and holds an Executive MBA from HEC Paris (France) / Babson Massachusetts (USA).
About biolog-id:
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005747/en/
Contact information
Astrid Billard, astrid.billard@biolog-id.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Andersen Global Strengthens West Africa Platform with the Addition of Member Firm in Ghana21.4.2026 16:30:00 EEST | Press release
Andersen Global continues its expansion across Africa, with Lima Partners joining as a member firm and introducing the Andersen name in Ghana. Established in 2014 and headquartered in Accra, Andersen in Ghana is led by Managing Partner Daniel Addo Okoe. The firm provides a full range of professional services, including tax advisory, regulatory compliance, accounting and advisory, transfer pricing, payroll administration, immigration, and company secretarial services to both local and international clients operating in Ghana and the wider West African region. “Becoming a member firm of Andersen Global marks a significant milestone for our organization,” said Kwame Amporful, senior partner of Andersen in Ghana. “Our clients will benefit from enhanced cross-border capabilities while continuing to receive practical, high-quality advisory services tailored to the Ghanaian market.” “Ghana plays a vital role in facilitating cross-border trade and investment within West Africa,” added Mark L.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom